516 results found
Bethel MA, Patel RA, Merrill P, et al., 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, LANCET DIABETES & ENDOCRINOLOGY, Vol: 6, Pages: 105-113, ISSN: 2213-8587
Dzudie A, Rayner B, Ojji D, et al., 2018, Roadmap to Achieve 25% Hypertension Control in Africa by 2025., Glob Heart, Vol: 13, Pages: 45-59
BACKGROUND: The Pan-African Society of Cardiology (PASCAR) has identified hypertension as the highest area of priority action to reduce heart disease and stroke on the continent. OBJECTIVES: The aim of this PASCAR roadmap on hypertension was to develop practical guidance on how to implement strategies that translate existing knowledge into effective action and improve detection, treatment and control of hypertension and cardiovascular health in sub-Saharan Africa (SSA) by the year 2025. METHODS: Development of this roadmap started with the creation of a consortium of experts with leadership skills in hypertension. In 2014, experts in different fields, including physicians and nonphysicians, were invited to join. Via face-to-face meetings and teleconferences, the consortium made a situation analysis, set a goal, identified roadblocks and solutions to the management of hypertension and customized the World Heart Federation roadmap to Africa. RESULTS: Hypertension is a major crisis on the continent but very few randomized controlled trials have been conducted on its management. Also, only 25.8% of the countries have developed or adopted guidelines for management of hypertension. Other major roadblocks are either government and health-system related or health care professional or patient related. The PASCAR hypertension task force identified a 10-point action plan to be implemented by African ministries of health to achieve 25% control of hypertension in Africa by 2025. CONCLUSIONS: Hypertension affects millions of people in SSA and if left untreated, is a major cause of heart disease and stroke. Very few SSA countries have a clear hypertension policy. This PASCAR roadmap identifies practical and effective solutions that would improve detection, treatment and control of hypertension on the continent and could be implemented as is or adapted to specific national settings.
Jun M, Ohkuma T, Zoungas S, et al., 2018, Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON., Diabetes Care, Vol: 41, Pages: 163-170
OBJECTIVE: To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS: Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease in UACR was not significantly associated with lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75-0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS: Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.
Mohammedi K, Chalmers J, Herrington W, et al., 2018, Associations between body mass index and the risk of renal events in patients with type 2 diabetes., Nutr Diabetes, Vol: 8
BACKGROUND/OBJECTIVES: We aimed to evaluate the relationship between BMI and the risk of renal disease in patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study. SUBJECTS/METHODS: Participants were divided into six baseline BMI categories: <18.5 (underweight, n = 58); ≥18.5 to <25 (normal, n = 2894); ≥25 to <30 (overweight, n = 4340); ≥30 to <35 (obesity grade 1, n = 2265); ≥35 to <40 (obesity grade 2, n = 744); and ≥40 kg/m2 (obesity grade 3, n = 294); those underweight were excluded. The composite outcome "major renal event" was defined as development of new macroalbuminuria, doubling of creatinine, end stage renal disease, or renal death. These outcomes and development of new microalbuminuria were considered individually as secondary endpoints. RESULTS: During 5-years of follow-up, major renal events occurred in 487 (4.6%) patients. The risk increased with higher BMI. Multivariable-adjusted HRs (95% CIs), compared to normal weight, were: 0.91 (0.72-1.15) for overweight; 1.03 (0.77-1.37) for obesity grade 1; 1.42 (0.98-2.07) for grade 2; and 2.16 (1.34-3.48) for grade 3 (p for trend = 0.006). These findings were similar across subgroups by randomised interventions (intensive versus standard glucose control and perindopril-indapamide versus placebo). Every additional unit of BMI over 25 kg/m2 increased the risk of major renal events by 4 (1-6)%. Comparable results were observed with the risk of secondary endpoints. CONCLUSIONS: Higher BMI is an independent predictor of major renal events in patients with type 2 diabetes. Our findings encourage weight loss to improve nephroprotection in these patients.
Pieber TR, Marso SP, McGuire DK, et al., 2018, DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality, DIABETOLOGIA, Vol: 61, Pages: 58-65, ISSN: 0012-186X
Zinman B, Marso SP, Poulter NR, et al., 2018, Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2), DIABETOLOGIA, Vol: 61, Pages: 48-57, ISSN: 0012-186X
Atkins ER, Hirakawa Y, Salam A, et al., 2017, Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1318-1325, ISSN: 0263-6352
Blomster JI, Zoungas S, Woodward M, et al., 2017, The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study, DIABETES RESEARCH AND CLINICAL PRACTICE, Vol: 127, Pages: 212-217, ISSN: 0168-8227
Bunker J, Chang C-L, Chapman N, et al., 2017, True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation, JOURNAL OF CLINICAL HYPERTENSION, Vol: 19, Pages: 250-255, ISSN: 1524-6175
Crossan C, Dehbi H-M, Williams H, et al., 2017, Economic evaluation of a polypill for the treatment of patients with established or at high risk of cardiovascular disease (CVD): a UK-National Health Service study, Publisher: NATURE PUBLISHING GROUP, Pages: 664-664, ISSN: 0950-9240
Crossan CJ, Dehbi H, Thom S, et al., 2017, COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING, Publisher: ELSEVIER SCIENCE INC, Pages: A620-A620, ISSN: 1098-3015
Glaysher MA, Mohanaruban A, Prechtl CG, et al., 2017, A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus, BMJ OPEN, Vol: 7, ISSN: 2044-6055
Gupta A, Thompson D, Whitehouse A, et al., 2017, Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase, LANCET, Vol: 389, Pages: 2473-2481, ISSN: 0140-6736
Holman RR, Bethel MA, Mentz RJ, et al., 2017, Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes., N Engl J Med, Vol: 377, Pages: 1228-1239
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those
Kraja AT, Cook JP, Warren HR, et al., 2017, New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475000 Individuals, CIRCULATION-CARDIOVASCULAR GENETICS, Vol: 10, ISSN: 1942-325X
Liu DJ, Peloso GM, Yu H, et al., 2017, Exome-wide association study of plasma lipids in > 300,000 individuals, NATURE GENETICS, Vol: 49, Pages: 1758-+, ISSN: 1061-4036
Marso SP, McGuire DK, Zinman B, et al., 2017, Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 377, Pages: 723-732, ISSN: 0028-4793
Mentz RJ, Bethel MA, Gustavson S, et al., 2017, Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), AMERICAN HEART JOURNAL, Vol: 187, Pages: 1-9, ISSN: 0002-8703
Messerli FH, Hofstetter L, Agabiti-Rosei E, et al., 2017, Expertise: no longer a sine qua non for guideline authors?, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1564-1566, ISSN: 0263-6352
Mohammedi K, Woodward M, Marre M, et al., 2017, Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes, CARDIOVASCULAR DIABETOLOGY, Vol: 16, ISSN: 1475-2840
Noordam R, Sitlani CM, Avery CL, et al., 2017, A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, JOURNAL OF MEDICAL GENETICS, Vol: 54, Pages: 313-323, ISSN: 0022-2593
Ohkuma T, Woodward M, Jun M, et al., 2017, Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus The ADVANCE-ON Study, HYPERTENSION, Vol: 70, Pages: 461-+, ISSN: 0194-911X
Poulter N, Mann JFE, Brown-Frandsen K, et al., 2017, Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial, DIABETIC MEDICINE, Vol: 34, Pages: 23-24, ISSN: 0742-3071
Poulter NR, Lackland DT, 2017, May Measurement Month: a global blood pressure screening campaign, LANCET, Vol: 389, Pages: 1678-1680, ISSN: 0140-6736
Poulter NR, Schutte AE, Tomaszewski M, et al., 2017, May Measurement Month: a new joint global initiative by the International Society of Hypertension and the World Hypertension League to raise awareness of raised blood pressure, JOURNAL OF HYPERTENSION, Vol: 35, Pages: 1126-1128, ISSN: 0263-6352
Stam-Slob MC, Visseren FLJ, Jukema JW, et al., 2017, Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients, CLINICAL RESEARCH IN CARDIOLOGY, Vol: 106, Pages: 58-68, ISSN: 1861-0684
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.